Svetloćelijski/endometrioidni karcinom jajnika udružen sa endometriozom u istom jajniku
Sažetak
Uvod. Endometrioza jajnika je identifikovana kao faktor rizika od nastanka karcinoma jajnika udruženog sa endometriozom. Prikazali smo bolesnicu sa istovremenom pojavom svetloćelijskog/endometrioidnog tipa karcinoma jajnika i endometrioze u istom jajniku. Prikaz bolesnika. Bolesnica, stara 47 godina, podvrgnuta je operativnom zahvatu zbog endometriotične ciste na desnom jajniku. Urađena je histerektomija sa obostranom adneksektomijom, limfadenektomija regije desnog slabinskog mišića, omentektomija i višestruke biopsije peritoneuma. Posle operacije primenjena je hemioterapija u toku šest ciklusa po protokolu Taxol-CBDCA. Nakon hiruškog zahvata i sprovedenog lečenja hemioterapijom urađen je kontrolni CT abdomena i male karlice i kod bolesnice nisu nađeni znakovi recidiva bolesti. Šest meseci posle završenog lečenja bolesnica se dobro osećala i nije imala recidiv bolesti. Zaključak. Svetloćelijski i endometrioidni podtip karcinoma jajnika imaju dobru prognozu ako se otkriju i leče u ranom stadijumu bolesti. Kod prikazane bolesnice karcinom je otkriven u prvom stadijumu i uspešno je lečen kombinovanom terapijom tj. hiruški i hemioterapijom.
Reference
Lyttle B, Bernardi L, Pavone ME. Ovarian cancer in endometri-osis: Clinical and molecular aspects. Minerva Ginekol 2014; 66(2): 155‒64.
Forte A, Cipollaro M, Galderisi U. Genetic, epigenetic and stem cell alterations in endometriosis: New insights and potential therapeutic perspectives. Clin Sci 2014; 126(2): 123‒38.
Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: Links, risks, and challenges faced. Int J Womens Health 2015; 7: 663‒72.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69‒90.
Wang S, Qiu L, Lang JH, Shen K, Yang JK, Huang MF, et al. Clinical analysis of ovarian epithelial carcinoma with coexist-ing pelvic endometriosis. Am J Obstet Gynecol 2013; 208: 413.e1–413.e5.
Burghaus S, Häberle L, Schrauder M, Heusinger K, Thiel F, Hein A, et al. Endometriosis as a risk factor for ovarian or endome-trial cancer-results of a hospital-based case control study. BMC Cancer 2015; 15: 751.
Noli S, Cipriani S, Scarfone G, Villa A, Grossi E, Monti E, et al. Long term survival of ovarian endometriosis associated clear cell and endometrioid ovarian cancers. International journal of gynecological cancer 2013; 23(2): 244‒8.
Ma X, Hui Y, Lin L, Wu Y, Zhang X, Qin X. Possible rele-vance of tumor-related genes mutation to malignant transfor-mation of endometriosis. Eur J Gynaecol Oncol 2016; 37(1): 89‒94.
Suryawanshi S, Huang X, Elishaev E, Budiu RA, Zhang L, Kim S, et al. Complement pathway is frequently altered in endome-triosis and endometriosis-associated ovarian cancer. Clin Can-cer Res 2014; 20(23): 6163‒74.
Borrelli GM, Abrão MS, Taube ET, Darb-Esfahani S, Köhler C, Chiantera V, et al. (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Mol Hum Reprod 2016; 22(5): 329‒37.
Rechsteiner M, Zimmermann A, Wild PJ, Caduff R, Teichman A, Fink D, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 2013; 95(2): 235‒41.
Worley MJ, Liu S, Hua Y, Kwok JS, Samuel A, Hou L, et al. Mo-lecular changes in endometriosis-associated ovarian clear cell carcinoma. Eur J Cancer 2015; 51(13): 1831‒42.
Helder-Woolderink JM, Blok EA, Vasen HFA, Hollema H, Mour-its MJ, De De Bock GH. Ovarian cancer in Lynch syndrome: as systematic review. Eur J Cancer 2016; 55: 65-73.
Teixeira N, Mourits MJ, Vos JR, Kolk DM, Jansen L, Oosterwijk JC, et al. Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. Maturitas 2015; 82(2): 197‒202.